Development Consortium Research Articles

President’s Address, 22nd Biennial International Conference of the International Consortium for Social Development, Johannesburg, South Africa, 13–16 July 2021

The president’s address includes welcome and concluding speeches covering the main global issues of the time, the acknowledgment of organizers, Social Development Leadership awards, the summary of achievements in the first term, and vision for the International Consortium for Social Development in the second term.

International Consortium for Social Development: Members’ Views and Future Directions

This article aims to discuss members’ views about the past and current engagements and activities of the International Consortium for Social Development (ICSD), and the future directions and strategies. A survey method was employed to collect data from the ICSD members by using the SurveyMonkey software. Quantitative data analysis was limited to frequency distributions, and responses to open-ended questions were analyzed by using the qualitative content analysis method. Further, these results were presented in a workshop to generate ideas for the future directions and strategies. Overall, the analysis showed that the members had positive perceptions of the ICSD in terms of meeting their expectations and conduct of activities according to its mission. Some of the critical issues and the future directions for the ICSD included relooking at the leadership, finance, membership, social development vision, and knowledge-building by research and scholarly activities and networking, education/curriculum programs, conferences and practice projects, and activism and increasing visibility. The article argues that addressing these and similar issues are critical in maintaining and sustaining consortiums/professional bodies such as the ICSD. The findings and analysis have implications for improving and strengthening the ICSD and similar professional bodies.

Statement of Ethics for the International Consortium for Social Development (ICSD)

Background: In June 2019, Professor Manohar Pawar, President of the ICSD, constituted a committee, comprising Prof. Richard Hugman, University of New South Wales, Prof. Manohar Pawar, Charles Sturt University, and Prof. Vijayan K. Pillai, University of Texas at Arlington, to develop a draft statement of ethics for the ICSD. The statement was circulated for ICSD members’ feedback. The feedback received from members, including, Drs. Michael A. Dover, Gokul Mandayam, and Francis Okello, was used to revise the statement. The following statement of ethics for the ICSD is an evolving document for the benefit of development practitioners and it is hoped that ICSD members would further refine and strengthen it periodically.

RAMPVIS: Answering the challenges of building visualisation capabilities for large-scale emergency responses

The effort for combating the COVID-19 pandemic around the world has resulted in a huge amount of data, e.g., from testing, contact tracing, modelling, treatment, vaccine trials, and more. In addition to numerous challenges in epidemiology, healthcare, biosciences, and social sciences, there has been an urgent need to develop and provide visualisation and visual analytics (VIS) capacities to support emergency responses under difficult operational conditions. In this paper, we report the experience of a group of VIS volunteers who have been working in a large research and development consortium and providing VIS support to various observational, analytical, model-developmental, and disseminative tasks. In particular, we describe our approaches to the challenges that we have encountered in requirements analysis, data acquisition, visual design, software design, system development, team organisation, and resource planning. By reflecting on our experience, we propose a set of recommendations as the first step towards a methodology for developing and providing rapid VIS capacities to support emergency responses.

Biomaterials as a Vital Frontier for Stem Cell-Based Tissue Regeneration.

Biomaterials and tissue regeneration represent two fields of intense research and rapid advancement. Their combination allowed the utilization of the different characteristics of biomaterials to enhance the expansion of stem cells or their differentiation into various lineages. Furthermore, the use of biomaterials in tissue regeneration would help in the creation of larger tissue constructs that can allow for significant clinical application. Several studies investigated the role of one or more biomaterial on stem cell characteristics or their differentiation potential into a certain target. In order to achieve real advancement in the field of stem cell-based tissue regeneration, a careful analysis of the currently published information is critically needed. This review describes the fundamental description of biomaterials as well as their classification according to their source, bioactivity and different biological effects. The effect of different biomaterials on stem cell expansion and differentiation into the primarily studied lineages was further discussed. In conclusion, biomaterials should be considered as an essential component of stem cell differentiation strategies. An intense investigation is still required. Establishing a consortium of stem cell biologists and biomaterial developers would help in a systematic development of this field.

Synergistic role of bacterial consortium (RKS-AMP) for treatment of recalcitrant coloring pollutants of textile industry wastewater

In this study, a bacterial consortium (RKS-AMP) was developed, which showed 99.28% decolorization of RCPs with significant reduction in COD (88.77%), BOD (93.99%), TOC (72.53%), phenol (85.90%) within 15 h at 30 ± 2 °C, pH 7, inoculum size (10%), salt concentration (1%), static condition in presence of glucose and yeast extract as carbon and nitrogen source, respectively. It also removed 72.35% of (Cr), 79.09% of (Cd), 65.88% (As) and Pb (83.87%) at same conditions. During RCPs treatment, lignin peroxidase (LiP), manganese peroxidase (MnP) and laccase enzyme activities were also recorded indicating that these enzymes are involved in RCPs degradation. The RCPs present in TIWW and their metabolites produced during the treatment process were identified by FT-IR and GC–MS analysis. In addition, the toxicity studies showed that metabolites of RCPs allowed 100–90% seed germination with significant improvement in root length, shoot length and biomass production in Vigna radiata and Vigna mungo indicating that the developed bacterial consortium (RKS-AMP) was effective in degradation and detoxification of RCPs. Thus, this newly developed bacterial consortium (RKS-AMP) can be used effectively in degradation and detoxification of textile industry wastewater pollutants.

Development of a bacterial consortium from Variovorax paradoxus and Pseudomonas veronii isolates applicable in the removal of BTEX

In this study, we report on the development of a novel bacterial consortium, consisting of Variovorax paradoxus and Pseudomonas veronii isolates, applicable in the biodegradation of all six BTEX compounds (benzene, toluene, ethylbenzene, o-, m- and p-xylene) and the bioremediation of contaminated sites. The co-cultivability of the selected bacterial isolates was determined in nutrient-rich medium, as well as in BTEX amended mineral salts solution using Terminal Restriction Fragment Length Polymorphism (T-RFLP) and CFU determinations. BTEX biodegradation capacity of the two-strain consortium was assessed in mineral salts solution, where a series of BTEX depletions and supplementations occurred, as well as in a real, BTEX polluted environmental sample (contaminated groundwater) in the presence of the autochthonous bacterial community. The obtained results indicated that the developed bacterial consortium is very efficient in BTEX biodegradation. Under laboratory conditions, the acclimatized bacterial consortium completely degraded the BTEX mixture with a concentration as high as 20 mg l−1 in a mineral salt medium within a short span of 6 h. Close to in situ groundwater conditions (incubated at 15 °C under static conditions in the absence of light), groundwater microcosms containing the autochthonous bacterial community inoculated with the developed bacterial consortium showed more efficient toluene, o-, m-and p-xylene biodegradation capacity than microcosms containing solely the native microbial population originally found in the groundwater. In the inoculated microcosms, after 115 h of incubation the concentration (~ 1.7 mg l−1 each) of o-, m- and p-xylene decreased to zero, whereas in the non-inoculated microcosms the concentration of xylene isomers was still 0.2, 0.3 and 0.3 mg l−1, respectively. The allochthonous bioaugmentation of the contaminated groundwater with the obtained inoculant was successful and manifested in a better BTEX degradation rate. Our results suggest that the obtained bacterial consortium can be a new, stable and efficient bioremediation agent applicable in the synergistic elimination of BTEX compounds from contaminated sites.

Optimization of a Two-Species Microbial Consortium for Improved Mcl-PHA Production From Glucose-Xylose Mixtures.

Polyhydroxyalkanoates (PHAs) have attracted much attention as a good substitute for petroleum-based plastics, especially mcl-PHA due to their superior physical and mechanical properties with broader applications. Artificial microbial consortia can solve the problems of low metabolic capacity of single engineered strains and low conversion efficiency of natural consortia while expanding the scope of substrate utilization. Therefore, the use of artificial microbial consortia is considered a promising method for the production of mcl-PHA. In this work, we designed and constructed a microbial consortium composed of engineered Escherichia coli MG1655 and Pseudomonas putida KT2440 based on the “nutrition supply–detoxification” concept, which improved mcl-PHA production from glucose-xylose mixtures. An engineered E. coli that preferentially uses xylose was engineered with an enhanced ability to secrete acetic acid and free fatty acids (FFAs), producing 6.44 g/L acetic acid and 2.51 g/L FFAs with 20 g/L xylose as substrate. The mcl-PHA producing strain of P. putida in the microbial consortium has been engineered to enhance its ability to convert acetic acid and FFAs into mcl-PHA, producing 0.75 g/L mcl-PHA with mixed substrates consisting of glucose, acetic acid, and octanoate, while also reducing the growth inhibition of E. coli by acetic acid. The further developed artificial microbial consortium finally produced 1.32 g/L of mcl-PHA from 20 g/L of a glucose–xylose mixture (1:1) after substrate competition control and process optimization. The substrate utilization and product synthesis functions were successfully divided into the two strains in the constructed artificial microbial consortium, and a mutually beneficial symbiosis of “nutrition supply–detoxification” with a relatively high mcl-PHA titer was achieved, enabling the efficient accumulation of mcl-PHA. The consortium developed in this study is a potential platform for mcl-PHA production from lignocellulosic biomass.

Models for an Ultraviolet-C Research and Development Consortium.

The development of an international, precompetitive, collaborative, ultraviolet (UV) research consortium is discussed as an opportunity to lay the groundwork for a new UV commercial industry and the supply chain to support this industry. History has demonstrated that consortia can offer promising approaches to solve many common, current industry challenges, such as the paucity of data regarding the doses of ultraviolet-C (UV-C, 200 nm to 280 nm) radiation necessary to achieve the desired reductions in healthcare pathogens and the ability of mobile disinfection devices to deliver adequate doses to the different types of surfaces in a whole-room environment. Standard methods for testing are only in the initial stages of development, making it difficult to choose a specific UV-C device for a healthcare application. Currently, the public interest in UV-C disinfection applications is elevated due to the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the respiratory coronavirus disease 19 (COVID-19). By channeling the expertise of different UV industry stakeholder sectors into a unified international consortium, innovation in UV measurements and data could be developed to support test methods and standards development for UV healthcare equipment. As discussed in this paper, several successful examples of consortia are applicable to the UV industry to help solve these types of common problems. It is anticipated that a consortium for the industry could lead to UV applications for disinfection becoming globally prolific and commonplace in residential, work, business, and school settings as well as in transportation (bus, rail, air, ship) environments. Aggressive elimination of infectious agents by UV-C technologies would also help to reduce the evolution of antibiotic-resistant bacteria.

Gestational Weight Gain and Adverse Maternal and Neonatal Outcomes for Pregnancies Complicated by Pregestational and Gestational Diabetes.

This study aimed to investigate the association between excess and less than recommended gestational weight gain (GWG) and adverse maternal and neonatal outcomes in women with pregestational and gestational diabetes. We conducted a secondary analysis of the National Institute of Child Health and Human Development (NICHD) Consortium on Safe Labor (CSL) study. We included deliveries >23 weeks of nonanomalous singletons with either pregestational or gestational diabetes. The exposure was GWG greater than or less than compared with the U.S. Institute of Medicine recommendations for total pregnancy weight gain per prepregnancy body mass index. Consistent with the 2020 Delphi outcome for diabetes in pregnancy, maternal outcomes included cesarean delivery and preeclampsia and neonatal outcomes included small for gestational age (SGA), large for gestational age (LGA), macrosomia >4,000 g, preterm birth <37 weeks, stillbirth, and neonatal death. We modeled both absolute GWG and GWG z-scores, standardized for gestational duration. Multivariable logistic regression with generalized estimating equations was used, adjusting for age, race/ethnicity, parity, prior cesarean delivery, chronic hypertension, tobacco use, U.S. region, and delivery year. Of 8,322 deliveries (n = 8,087 women) complicated by pregestational or gestational diabetes, 47% were in excess, 27% were within, and 26% were less than GWG recommendations. Deliveries with excess absolute GWG were at higher adjusted odds of cesarean delivery, preeclampsia, LGA, and macrosomia, compared with those within recommendations. Similar results were observed when using standardized GWG z-scores, in addition to higher likelihood of preterm birth and neonatal death. Less than recommended GWG was associated with a lower likelihood of these adverse outcomes but higher SGA. Additionally, less GWG by z-score was associated with a lower likelihood of stillbirth. Excess GWG increases the risk of adverse maternal and neonatal outcomes for women with pregestational and gestational diabetes. Less GWG than recommended may decrease this risk. · Understanding the impact of GWG modeled using both absolute and standardized measures is needed.. · Among pregnant women with diabetes, excess GWG was common and increased the risk of adverse outcomes and less than recommended GWG may decrease the risk of adverse outcomes, including stillbirth.. · Current recommendations may require revision for women with diabetes in pregnancy..

UNITE4TB: a new consortium for clinical drug and regimen development for TB.

UNITE4TB: a new consortium for clinical drug and regimen development for TB.

Creative strategies for spatial policy making in Brazilian ‘new left regionalism’: fighting inequalities and COVID-19 in the north-east region

Abstract The literature on the new regionalism has highlighted the leading role played by regions in the contemporary process of state rescaling and the governance of policy-making. We argue that a (re)politicisation of North-east Brazil and the emergence of a new left regionalism are underway. We examine the political and socioeconomic circumstances of this process through the creation of the Interstate Consortium for the Sustainable Development of the North-east. We conclude that while many challenges still lie ahead, this experience has demonstrated potential for the coherence of policies, and for constituting new political actors and arenas for the concertation of interests.

Decolorization of mixture of UV/ TiO2 pre-treated azo dyes by using developed bacterial consortium – An excellent outcome

The degradation of the mixture of azo dyes by the developed bacterial consortium, photocatalytic process (TiO2/UV) and their combined effects were investigated in this study. The bacteria consortium was developed from waste disposal drains in the local textile dyeing industry. The consortium consists of two different bacteria which were identified as Stenotrophomonas pavanii and Bacillus licheniformis through 16S rDNA sequence alignment. The decolorization efficiency was estimated by spectrophotometry and it was observed that biological and photochemical methods alone could not effectively remove the dyes as the decolorization efficiency was low and the absorption peak in the UV region was not completely removed. After 5 days of incubation at 37°C, pH 7 and a dye concentration of 150 mg/L, the microbial dye degradation reached a decolorization efficiency of more than 55%. Additionally, the UV treatment alone was also able to decolorize the dye less than 20% at 45°C, pH 9 at 150 mg/L of dye. A two-step treatment process, namely, photocatalytic treatment followed by biological degradation, was assessed. Ultraviolet-Visible (UVVis) spectral analysis showed that the combined effects were most efficient in the dye degradation (97-98%) which involved a complex interaction of enzyme activity, biosorption and photocatalytic action. Here we also report the optimization of various operational parameters.

Vírusellenes terápiás lehetőségek COVID–19 fertőzés kezelésére

Összefoglaló. A COVID–19-járvány egyre növekvő számú fertőzött betegének ellátása érdekében rövid időn belül szükség mutatkozott vírusellenes terápiás lehetőségekre. A gyors reagálás szempontját figyelembe véve erre a célra elsősorban más vírusok ellen már kifejlesztett vírusellenes szerek jöhetnek szóba. A magyar betegek ellátásbiztonsága szempontjából különösen fontos a hatóanyagok és gyógyszerkészítmények hazai gyártása. Ezt a cél tűzte ki a favipiravir, egy széles spektrumú antivirális hatóanyag hazai fejlesztése, amely sikeresen befejeződött, a gyógyszerkészítmény klinikai vizsgálata folyamatban van. Summary. Increasing impact of COVID-19 on the healthcare system prompted the identification of potential antiviral therapies. Due to the immediate demand, known drugs were subjected to repositioning attempts. These drugs include agents inhibiting the viral entry into the host cells, drugs potentially blocking the release of the viral RNA from the endosomes, antivirals inhibiting the replication of the viral RNA and finally compounds that might prevent the assembly of the new virion. Since there is less experience with camostat and nafamostat, the entry inhibitors tested in Japan, and due to the ambiguous data collected with the endosome blocking chloroquine and hydroxyl-chloroquine, we focused on the actual antiviral treatment options for COVID-19 infections. In addition to favipiravir and remdesivir that were used early, at the onset of the pandemic, we discuss novel candidates including molnupiravir, a promising antiviral actually investigated in clinical trials. Considering the needs of Hungarian COVID patients and the security of supply as first priority, we selected favipiravir and developed a convenient process for the industry-scale production of the active pharmaceutical ingredient (API). At the end of this review we summarize the development and clinical investigation of favipiravir, a wide spectrum antiviral drug used for the treatment of mild and moderate COVID patients in Hungary in both ambulant and clinical settings. The Hungarian COVID Task Force set up two consortia, one for the development and the other for the clinical investigations of favipiravir. The objective of the favipiravir development consortium was to develop processes for the production of Favipiravir API and dosage forms. The consortium completed the pilot plant scale industrial production of the API and produced clinical samples for the upcoming trials. The selection and laboratory scale optimization of the synthesis route was performed at the Medicinal Chemistry Research Group of the Research Center for Natural Sciences. The laboratory scale synthesis was scaled up for pilot plant production at EVI plc and Gedeon Richter plc. GMP production was realized at the facilities of Gedeon Richter plc. Finished dosage forms were developed at Meditop Ltd who produced the clinical samples under GMP conditions. The clinical consortium is headed by the Hungarian section of the European Clinical Research Infrastructure Network (ECRIN) and organized two trials. One of these trials investigates favipiravir produced in Hungary while the other trial is performed with favipiravir produced in Japan. Both studies were approved by the Hungarian regulatory agency (OGYÉI) and are ongoing.

International Consortium for Social Development: Members’ Views and Future Directions

This article aims to discuss members’ views about the past and current engagements and activities of the International Consortium for Social Development (ICSD), and the future directions and strategies. A survey method was used to collect data from the ICSD members by using the Survey Monkey software. Quantitative data analysis was limited to frequency distributions, and responses to open-ended questions were analysed by using the qualitative content analysis method. Further, these results were presented in a workshop to generate ideas for the future directions and strategies. Overall, the analysis showed that the members had positive perceptions of the ICSD in terms of meeting their expectations and conduct of activities according to its mission. Some of the critical issues and the future directions for the ICSD included relooking at the leadership, finance, membership, social development vision and knowledge building by research and scholarly activities and networking, education/curriculum programmes, conferences and practice projects, and activism and increasing visibility. The article argues that addressing these and similar issues is critical in maintaining and sustaining consortiums/professional bodies such as the ICSD. The findings and analysis have implications for improving and strengthening the ICSD and similar professional bodies.

NCI Awardee Skills Development Consortium (NASDC): Applicant profiles.

11030 Background: In 2020, the NCI funded a new educational consortium, NASDC (NCI Awardee Skills Development Consortium, RFA-CA-19-010 and -011), through four institutionally granted UE5 awards to deliver a specific course each and a U24 award as a Coordinating Center. The goal is to teach current early-career faculty NCI grantees skills in areas critical for successful independent academic cancer research careers. Courses focus on leadership and socioemotional skills, health disparities, immuno-oncology, and cell and gene therapy. Teaching will initially be virtual, given the COVID pandemic. Methods: A steering committee and four working groups were established to build the consortium infrastructure, including the NASDC (osu.edu) website. Clientele are early-career faculty PD/PI of a current NCI-funded grant (K01, K07, K08, K22, K23, K25, R00, R21, DP1, DP2, DP5, R01, R23, R29, R37, R56, RF1, RL1, U01), of whom 454 were directly contacted. Blast emails and social media were also used. We are reporting the characteristics of 154 applicants, who completed the RedCap application online. Results: 85% of the applicants are within the first 5 years of a faculty appointment, 87% at the assistant professor rank, and 65% on tenure track. 40% hold an M.D. degree and 72% a Ph.D. 81% are US citizens, 52% females, and 45/33/16/2/4%-11% are White/Asian/Black/Native Americans/Other–Hispanics/Latino. 76% work at NCI-designated comprehensive cancer centers. Mean protected research time is 80%. Non-mutually exclusive fields of research interest are therapeutics (46%), basic science (37%), disparities (34%) prevention (32%), public health (28%), and pediatrics (10%). 66% have received a K-award grant, 13% each an R21 or R00, and 3% an R01. Additionally, 35% had a second NCI grant as PI, 10% a third grant, and 60% had non-NCI grants. Reasons for applying included (1) not quite ready to lead a research team (42%), (2) need for stronger career mentoring (37%), and (3) not being fully confident in research skills (21%). Conclusions: Applicants to the new NCI educational consortium (NASDC) have a successful start to their academic career with a third having obtained more than one NCI award. Most applicants work at NCI-designated comprehensive cancer centers. As cancer research continues to evolve and has the potential to address critical health care needs of the nation, NASDC will strive to equip scientists to be leaders, teach advances in technology, and impart confidence in research skills.

ENABLE: an engine for European antibacterial drug discovery and development.

ENABLE is an antibacterial drug discovery and development consortium formed as a public–private partnership in 2014 as part of the Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme. With the project soon ending, here we provide a brief overview and reflect on its achievements, strengths and weaknesses. ENABLE is an antibacterial drug discovery and development consortium formed as a public–private partnership in 2014 as part of the Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme. With the project soon ending, here we provide a brief overview and reflect on its achievements, strengths and weaknesses.

Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements.

Subcutaneous (SC) delivery of biologics has traditionally been limited to fluid volumes of 1–2 mL, with recent increases to volumes of about 3 mL. This injection volume limitation poses challenges for high-dose biologics, as these formulations may also require increased solution concentration in many cases, resulting in high viscosities which can affect the stability, manufacturability, and delivery/administration of therapeutic drugs. Currently, there are technologies that can help to overcome these challenges and facilitate the delivery of larger amounts of drug through the SC route. This can be achieved either by enabling biologic molecules to be formulated or delivered as high-concentration injectables (>100 mg/mL for antibodies) or through facilitating the delivery of larger volumes of fluid (>3 mL). The SC Drug Delivery and Development Consortium, which was established in 2018, aims to identify and address critical gaps and issues in the SC delivery of high-dose/volume products to help expand this delivery landscape. Identified as a high priority out of the Consortium’s eight problem statements, it highlights the need to shift perceptions of the capabilities of technologies that enable the SC delivery of large-volume (>3 mL) and/or high-dose biologics. The Consortium emphasizes a patient-focused approach towards the adoption of SC delivery of large-volume/high-concentration dosing products to facilitate the continued expansion of the capabilities of novel SC technologies. To raise awareness of the critical issues and gaps in high-dose/volume SC drug development, this review article provides a generalized overview of currently available and emerging technologies and devices that could facilitate SC delivery of high-dose/volume drug formulations. In addition, it discusses the challenges, gaps, and future outlook in high-dose/volume SC delivery as well as potential solutions to exploit the full value of the SC route of administration.

Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a multi‐system disease characterized primarily by progressive muscle weakness. Cognitive dysfunction is commonly observed in patients; however, factors influencing risk for cognitive dysfunction remain elusive. Using sparse canonical correlation analysis (sCCA), an unsupervised machine‐learning technique, we observed that single nucleotide polymorphisms collectively associate with baseline cognitive performance in a large ALS patient cohort (N = 327) from the multicenter Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium. We demonstrate that a polygenic risk score derived using sCCA relates to longitudinal cognitive decline in the same cohort and also to in vivo cortical thinning in the orbital frontal cortex, anterior cingulate cortex, lateral temporal cortex, premotor cortex, and hippocampus (N = 90) as well as post‐mortem motor cortical neuronal loss (N = 87) in independent ALS cohorts from the University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Our findings suggest that common genetic polymorphisms may exert a polygenic contribution to the risk of cortical disease vulnerability and cognitive dysfunction in ALS.

High-Voltage Performance Enhancement of Nickel-Rich Cathode through Improved Binding Ability of Designed Binder

As mobile electronics and electric vehicles become essential in our lives, the specific energy density of a lithium-ion battery is one of the criteria that determines the quality of a battery and customers’ use range. Cathode is the one that primarily determines the capacity and energy density of the battery, and consists of active material, binder and carbon black. Nickel-rich layered oxides such as LiNi0.8Co0.1Mn0.1O2 (NCM811) are promising high-capacity cathode active materials, and its reversible capacity increases more by charging to higher cut-off voltages than the conventional 4.2 V. We observed that NCM811 cathode fabricated with commercial polyvinylidene fluoride binder has an unstable interface to electrolyte under high cut-off charge voltages and undergoes drastic structural changes during cycling in particular at elevated temperature, leading to capacity fade and reduced lifespan of the battery. In order to acquire a high reversible capacity and enhanced cycling performance with NCM811 cathode by mitigating the problems, we have designed an unique and functional high-voltage binder and make the combination with NCM811. In the meeting, we are going to report improved thermal stability and cycling performance of the designed binder-assisted cathode. Acknowledgement This research was supported by the Ministry of SMEs and Startups (S2788978) of Korea, National Research Foundation grant funded by the Korean Ministry of Science and ICT (No. 2019R1A2C1084024) and Creative Human Resource Development Consortium for Fusion Technology of Functional Chemical/Bio Materials of BK Plus program by Ministry of Education of Korea.